Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study

 Controls n = 2,131,223All Type 2 diabetes n = 421,855HbA1c categories at baseline (NGSP  %/IFCC mmol/mol)
 ≤ 6.9% (≤52 mmol/mol) n = 210,6557.0–7.8% (53–62 mmol/mol) n = 79,8767.9–8.7% (63–72 mmol/mol) n = 42,2308.8–9.6% (73–82 mmol/mol) n = 20,169≥ 9.7% (≥83 mmol/mol) n = 19,842Missing value n = 49,083
Women975,940 (45.8%)188,307 (44.6%)96,826 (46.0%)35,228 (44.1%)18,222 (43.1%)8287 (41.1%)7590 (38.3%)22,154 (45.1%)
Age (years)64.6 (12.5) n = 2,131,22364.7 (12.5) n = 421,85565.4 (12.2) n = 210,65565.9 (12.0) n = 79,87664.6 (12.3) n = 42,23062.8 (12.5) n = 20,16960.2 (12.6) n = 19,84262.7 (14.0) n = 49,083
Age category 
 < 55 years424,662 (19.9%)83,356 (19.8%)37,566 (17.8%)13,480 (16.9%)8490 (20.1%)4983 (24.7%)6261 (31.6%)12,576 (25.6%)
 55–64 years606,294 (28.4%)118,424 (28.1%)57,891 (27.5%)22,234 (27.8%)12,254 (29.0%)6170 (30.6%)6501 (32.8%)13,374 (27.2%)
 65–74 years623,184 (29.2%)122,848 (29.1%)64,271 (30.5%)23,789 (29.8%)11,855 (28.1%)5252 (26.0%)4459 (22.5%)13,222 (26.9%)
 75 + years477,083 (22.4%)97,227 (23.0%)50,927 (24.2%)20,373 (25.5%)9631 (22.8%)3764 (18.7%)2621 (13.2%)9911 (20.2%)
Born in Sweden1,862,552 (87.4%)343,748 (81.6%)175,599 (83.4%)65,386 (81.9%)34,031 (80.7%)16,015 (79.5%)15,134 (76.4%)37,583 (76.6%)
Education category 
 Low751,922 (35.9%)176,826 (42.9%)87,269 (42.3%)35,461 (45.5%)18,982 (46.2%)8804 (45.0%)7772 (40.4%)18,538 (39.0%)
 Mid833,045 (39.8%)168,052 (40.8%)84,216 (40.8%)31,074 (39.9%)16,334 (39.8%)7942 (40.6%)8488 (44.1%)19,998 (42.0%)
 High510,647 (24.4%)66,930 (16.3%)35,003 (17.0%)11,322 (14.5%)5758 (14.0%)2797 (14.3%)2993 (15.5%)9057 (19.0%)
Variables in the NDR only  
HbA1c (mmol/mol,  %) 54.3 (14.9) 7.12 (1.36) n = 372,77244.7 (5.0) 6.25 (0.46) n = 210,65556.5 (2.6) 7.33 (0.24) n = 79,87666.9 (2.8) 8.27 (0.26) n = 42,23076.9 (2.8) 9.19 (0.26) n = 20,16997.2 (12.6) 11.04 (1.16) n = 19,842 
Diabetes duration (years) 5.35 (7.08) n = 384,0963.98 (5.72) n = 192,5536.61 (7.25) n = 74,7958.01 (7.91) n = 39,7817.94 (8.05) n = 19,0415.46 (7.31) n = 18,5565.61 (9.29) n = 39,370
BMI (kg/m2) 29.8 (5.4) n = 316,10729.5 (5.2) n = 172,98530.0 (5.4) n = 66,30430.1 (5.4) n = 34,83630.5 (5.7) n = 16,41230.5 (5.9) n = 15,50330.1 (5.7) n = 10,067
LDL (mmol/L, mg/dL) 2.96 (0.97) 114.4 (37.3) n = 224,5972.94 (0.94) 113.6 (36.5) n = 128,2102.94 (0.96) 113.5 (37.2) n = 45,6922.94 (0.98) 113.6 (37.7) n = 22,3613.00 (1.00) 115.7 (38.5) n = 10,1953.25 (1.09) 125.5 (42.0) n = 98643.09 (1.00) 119.2 (38.8) n = 8275
Systolic Blood Pressure (mmHg) 140.0 (18.0) n = 359,010139.0 (17.6) n = 196,021141.2 (18.1) n = 74,411141.7 (18.3) n = 38,960141.9 (18.7) n = 18,305140.5 (19.0) n = 17,111139.1 (18.9) n = 14,202
Distolic Blood Pressure (mmHg) 78.7 (9.8) n = 359,01078.2 (9.6) n = 196,02178.7 (9.8) n = 74,41179.2 (9.9) n = 38,96080.0 (10.0) n = 18,30581.4 (10.4) n = 17,11179.3 (10.6) n = 14,202
Smoker
 No 279,514 (83.7%)153,404 (85.3%)58,293 (84.8%)30,196 (83.6%)13,833 (81.2%)12,477 (78.7%)11,311 (69.9%)
 Yes 54,265 (16.3%)26,412 (14.7%)10,477 (15.2%)5925 (16.4%)3196 (18.8%)3386 (21.3%)4869 (30.1%)
eGFR (MDRD) (cat.)
 CKD stage 1 (eGFR ≥90) 96,846 (32.2%)48,373 (29.2%)18,970 (31.3%)10,514 (34.9%)5758 (40.5%)7391 (51.2%)5840 (35.9%)
 CKD stage 2 (eGFR 60–89) 153,262 (50.9%)89,151 (53.9%)30,699 (50.7%)14,332 (47.5%)6132 (43.2%)5356 (37.1%)7592 (46.7%)
 CKD stage 3 (eGFR 30–59) 47,880 (15.9%)26,378 (15.9%)10,258 (16.9%)4954 (16.4%)2153 (15.2%)1579 (10.9%)2558 (15.7%)
 CKD stage 4 (eGFR 15–29) 2491 (0.8%)1208 (0.7%)537 (0.9%)293 (1.0%)142 (1.0%)102 (0.7%)209 (1.3%)
 CKD stage 5 (eGFR < 15 or dialysis) 508 (0.2%)277 (0.2%)66 (0.1%)54 (0.2%)18 (0.1%)19 (0.1%)74 (0.5%)
eGFR (CKD-EPI) (cat.)  
 CKD stage 1 (eGFR ≥ 90) 112,140 (37.3%)57,044 (34.5%)21,754 (35.9%)12,012 (39.8%)6583 (46.3%)8275 (57.3%)6472 (39.8%)
 CKD stage 2 (eGFR 60–89) 142,152 (47.2%)82,943 (50.2%)28,705 (47.4%)13,194 (43.8%)5529 (38.9%)4698 (32.5%)7083 (43.5%)
 CKD stage 3 (eGFR 30–59) 43,302 (14.4%)23,707 (14.3%)9374 (15.5%)4558 (15.1%)1910 (13.4%)1341 (9.3%)2412 (14.8%)
 CKD stage 4 (eGFR 15–29) 2850 (0.9%)1396 (0.8%)626 (1.0%)325 (1.1%)160 (1.1%)114 (0.8%)229 (1.4%)
 CKD stage 5 (eGFR < 15 or dialysis) 543 (0.2%)297 (0.2%)71 (0.1%)58 (0.2%)21 (0.1%)19 (0.1%)77 (0.5%)
Registrations in the IPR prior to baseline  
 Coronary heart disease (I20–I25)137,684 (6.5%)59,008 (14.0%)29,142 (13.8%)12,099 (15.1%)6360 (15.1%)2895 (14.4%)2224 (11.2%)6288 (12.8%)
 Heart failure (I50)36,679 (1.7%)16,996 (4.0%)7578 (3.6%)3512 (4.4%)2026 (4.8%)1041 (5.2%)848 (4.3%)1991 (4.1%)
 Valve disease (I05–I09, I34–I36)23,120 (1.1%)6079 (1.4%)3279 (1.6%)1133 (1.4%)539 (1.3%)264 (1.3%)186 (0.9%)678 (1.4%)
 Stroke (I61–I64)64,724 (3.0%)22,417 (5.3%)11,318 (5.4%)4317 (5.4%)2380 (5.6%)1007 (5.0%)802 (4.0%)2593 (5.3%)
 Cancer (C00–C97)176,394 (8.3%)37,135 (8.8%)19,885 (9.4%)6944 (8.7%)3198 (7.6%)1421 (7.0%)1245 (6.3%)4442 (9.0%)
  1. For categorical variables n (%) is presented. For continuous variables Mean (SD) is presented